ProLindac Produces 66% Disease Stabilization In Heavily-Pretreated Patients Within Phase II Study High Dose Groups. Kudos to the recently reactivated H*O*P*E blog for highlighting this nice report. There are plenty of attractive Phase II results that don't make it to "prime time " randomized Phase III trials but here's hoping we have a winner on our hands. Disease stabilization is a "soft" endpoint to report. The Cadillac endpoint to report is really survival benefit and that is usually what the FDA requires for approval except in cases where there are no meaningful alternatives. Disease stabilization may be sufficient depends on how ODAC is voting that week and whether FDA listens to them (as sometimes it doesn't--look at how Avastin got approved in breast cancer over the objections of ODAC).